Comparative Analysis of Data Acquisition and Study Protocols of Bioavailability and Bioequivalence Studies: Regulatory Guidelines of the USA, EMA and TGA

Bio-equivalence (BE) and Bio-availability (BA) studies are crucial for assessing the efficacy and safety of pharmaceutical products. Regulatory guidelines for these studies across the region, potentially impacting study design, data acquisition and regulatory submission. This comparative analysis examines the regulatory guidelines for BA and BE studies issued by the US FDA, European Medicines Agency (EMA) and Therapeutic Goods Administration (TGA) of Australia. A comprehensive review of regulatory documents, study protocols and literature were conducted to identify similarities and difference in data acquisition and study protocols. The analysis revealed variations in guidelines for study design, sampling schedules, analytical methods and statistical analysis. This study provides insights into the regulatory implications of these differences and recommends best practices for designing and conducting BA and BE studies. The findings of this analysis will facilitate regulatory harmonization, improve study efficiency and support the development of high-quality pharmaceutical products.